the effect of managing human melanoma xenograft bearing mice with doses of PF 03814735 more than the types we administered, of well tolerated by the animals. Growth of WM1158 MGP cancer cells at different time points following therapy with 10 uM of Aurora kinase inhibitor, PF 03814735. Controls were WM1158 MGP melanomas that were not addressed or received only DMSO. Following therapy with 10 uM of Aurora kinase inhibitor for 72 hours, WM1158 MGP natural product library melanoma cells were labeled with propidium iodide and afflicted by flow cytometry. WM1158 MGP cancer cells which were not addressed or received only DMSO served as controls. At 24 and 48 hours following therapy with 10 uM of the Aurora kinase chemical, WM1158 MGP melanoma cells were labeled with annexin V/propidium iodide and analyzed by flow cytometry. WM1158 MGP melanoma cells that had obtained only DMSO served as controls. Immunoblot analysis of WM1158 MGP melanoma cells, treated with Aurora kinase inhibitor for 24 hours or 48 hours and probed with an antibody to c PARP. Immunofluorescence analysis of WM1158 MGP cancer cells, Plastid treated with 10 uM of Aurora kinase inhibitor or incubated in the existence of DMSO for 24 hours or 48 hours, that were analyzed by TUNEL staining. WM1158 MGP melanoma cells that had encountered apoptosis are pseudocolored red, and fluorescent DAPI counterstained nuclei are pseudocolored orange. Figure 4. Aurora kinase chemical treatment of MGP melanoma cells. Morphology of MGP melanoma cells not treated, that received only DMSO, or were treated with 10 uM of Aurora kinase inhibitor for 24 or 48 hours. Immunoblot analysis of WM1158 MGP cancer cells, treated for 1 hour with Aurora kinase chemical, PF 03814735, at a dose of 10 nM, 100 nM, 1 uM, or 10 uM, that were probed with antibody to pFGFR 1, Aurora kinase A pT288, or pHisH3, and tubulin for loading control. Immunoblot analysis of WM1158 MGP melanoma cells, treated with 10 uM of Aurora kinase inhibitor for 24 hours or 48 hours and probed with antibody to Aurora A pT288 or tubulin for loading control. WM1158 MGP cancer cells not treated or treated with only DMSO served as controls. Immunoblot analysis of WM1158 MGP cancer cells incubated in the presence of fifty ng/mL Everolimus mTOR inhibitor of nocodazole for 20 hours, followed by addition of 10 uM of Aurora kinase inhibitor for 5, 10, or 60 minutes, that have been probed with an antibody to pHisH3. WM1158 MGP melanoma cells that obtained only DMSO for 5, 10, or 60 minutes or only 50 ng/mL of nocodazole for 5, 10, or 60 minutes served as controls. Immunofluorescence examination of WM1158 MGP cancer cells maybe not treated or treated with 10 uM of Aurora kinase inhibitor for 2 hours that have been stained with an antibody to Aurora kinase A pT288 and tubulin and counterstained with fluorescent DAPI.